Confluent (NASDAQ:CFLT – Get Free Report) had its price target boosted by investment analysts at Guggenheim from $35.00 to $38.00 in a note issued to investors on Wednesday,Benzinga reports. The firm ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

Guggenheim adjusted its outlook for New York Times Company (NYSE:NYT), reducing the price target from $55.00 to $52.00 while maintaining a Neutral rating on the stock. According to InvestingPro data, ...

Guggenheim has expanded its risk-management ... After holding large weights in corporates and bank loans in its early years, that stake had ‎shrunk to 5.1% of ‎assets at Dec. 31, 2019 ...

Investment-grade corporates were down to 16% by the end of the year, while the team more than halved the combined high-yield and bank-loan weighting to 7%. Former Guggenheim global CIO Scott ...

In a report released today, Michael Morris from Guggenheim maintained a Buy rating on Meta Platforms (META – Research Report), with a price ...

Fintel reports that on January 24, 2025, Guggenheim downgraded their outlook ... allocation in GEV by 39.97% over the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt ...

Fintel reports that on January 24, 2025, Guggenheim upgraded their outlook ... in 0VFA by 17.89% over the last quarter. Royal Bank Of Canada holds 20,949K shares representing 6.47% ownership ...

Bank of America Securities analyst Tim Anderson ... In a report released on January 17, Guggenheim also maintained a Buy rating on the stock with a $973.00 price target. LLY market cap is ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...